Application of combination of FASN inhibitor and PD-1 antibody drug in breast cancer immunotherapy
The reduction of GPX4 protein levels and combined with the use of PD-1 antibody drugs has significantly improved the immunotherapy effect of breast cancer, solved the problem of low drug resistance and immunotherapy efficiency of breast cancer treatment, and provided new therapeutic targets Points and optimization solutions.
Patent Information
- Application Number
- CN202411236867.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-22
AI Technical Summary
The high incidence and drug resistance of breast cancer have led to limited effectiveness of existing treatment methods. The search for new drug treatment targets and delay drug resistance has become a research hotspot, especially the low efficiency of breast cancer immunotherapy, and new developments are needed. Tumor immunotherapy methods.
Combining FASN inhibitors and PD-1 antibody drugs, the GPX4 protein level and inhibit its gene expression through FASN inhibitors are significantly reduced, and PD-1 antibody drugs are used in combination to enhance the effect of tumor immunotherapy and significantly inhibit the proliferation and migration ability of breast cancer cells. and significantly inhibit tumor growth.
The combined use of FASN inhibitors and PD-1 antibodies has significantly improved the effect of tumor immunotherapy. Compared with single PD-1 antibody treatment, it has higher tumor suppression ability, provides new breast cancer drug treatment methods and optimized solutions, with Significant practical value.
Smart Images

Figure CN118987228A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of breast cancer immunotherapy, and specifically to the application of a FASN inhibitor combined with a PD-1 antibody drug in breast cancer immunotherapy. Background Art
[0002] According to the latest global cancer burden data for 2020 released by the World Health Organization's International Agency for Research on Cancer (IARC, https: / / gco.iarc.fr / today), breast cancer topped the list with 2.26 million new cases, becoming the world's number one cancer. Currently, surgery combined with chemotherapy or radiotherapy is the main means of clinical treatment for breast cancer. Unfortunately, due to the extensive intratumor heterogeneity, resistance to treatment often occurs. Therefore, finding new drug treatment targets and delaying drug resistance have become research hotspots.
[0003] In recent years, immunotherapy technology has developed rapidly and has become a mainstream treatment option for many cancers, greatly improving the survival rate and quality of life of some cancer patients. Among them, immune checkpoint inhibitors (ICIs) improve the tumor microenvironment and activate the body's immune system to kill cancer cells, thus making new breakthroughs in tumor immunotherapy. It is worth noting that compared with melanoma and lung cancer, the efficacy of immunotherapy for breast cancer is still lower, so there is an urgent need to further study the reasons why patients lack response to such drugs and develop new methods to enhance the benefits of immunotherapy to guide precision medicine practice.
[0004] As a key enzyme in lipid synthesis, fatty acid synthase (FASN) plays an important role in regulating metabolism and tumorigenesis. FASN protein is widely expressed in most tissues. Studies have shown that FASN inhibitors can inhibit FASN-mediated tumor growth, but the role of FASN inhibitors in PD-1 antibody-mediated tumor immunotherapy is still unclear. Therefore, it is necessary to obtain a new tumor immunotherapy drug by studying the related mechanism of the combined use of FASN inhibitors and PD-1 antibodies.
[0005] To this end, the present invention provides the use of a FASN inhibitor combined with a PD-1 antibody drug in the immunotherapy of breast cancer. Summary of the invention
[0006] The purpose of the present invention is to solve the problems raised in the above-mentioned background technology and provide the use of FASN inhibitors combined with PD-1 antibody drugs in breast cancer immunotherapy.
[0007] The above-mentioned object of the present invention is achieved by the following technical solutions:
[0008] The present invention provides the use of a FASN inhibitor in preparing a drug for immunotherapy of cancer.
[0009] Furthermore, the cancer is breast cancer.
[0010] Furthermore, the FASN inhibitor includes but is not limited to orlistat.
[0011] The present invention also provides the use of a FASN inhibitor combined with a PD-1 antibody drug in the preparation of an immunotherapy drug for breast cancer.
[0012] Furthermore, the PD-1 antibody drug includes but is not limited to atezolizumab.
[0013] The present invention also provides a medicine, the active ingredients of which include: a FASN inhibitor and a PD-1 antibody drug.
[0014] Furthermore, the medicine also includes pharmaceutically acceptable excipients.
[0015] The difficulty and significance of the technical problem solved by the present invention are:
[0016] The incidence and mortality of breast cancer are on the rise, seriously threatening the life and health of women. At present, surgery combined with chemotherapy or radiotherapy is the main means of clinical treatment of breast cancer. Unfortunately, due to the existence of extensive intratumor heterogeneity, drug resistance to treatment is often produced. Therefore, finding new drug treatment targets and delaying drug resistance have become research hotspots. The inventors of this application have confirmed through a large number of experiments that FASN inhibitors can significantly reduce the proliferation and migration ability of breast cancer cells, and then when combined with PD-1 antibody drugs, the effect of tumor immunotherapy of PD-1 antibodies can be increased, and tumor growth can be better inhibited; compared with single PD-1 antibody treatment, the FASN inhibitors provided in the scheme of the present invention combined with PD-1 antibodies can significantly inhibit the growth level of tumors in mice, which is significantly higher than the use of commonly used antibody drugs alone. Therefore, FASN inhibitors combined with PD-1 antibody drugs have a significant effect on the effect of tumor immunotherapy and have good practical value.
[0017] It can be seen from the above technical solution that compared with the prior art, the present invention has the following beneficial effects:
[0018] 1. The application of the FASN inhibitor combined with the PD-1 antibody drug provided by the scheme of the present invention in the preparation of tumor immunotherapy drugs has been confirmed through a large number of experiments that the FASN inhibitor can significantly reduce the GPX4 protein level and inhibit the gene expression of GPX4, and further, when combined with the PD-1 antibody drug, it can increase the tumor immunotherapy effect of the PD-1 antibody and better inhibit tumor growth;
[0019] 2. Compared with single PD-1 antibody treatment, the FASN inhibitor combined with PD-1 antibody provided in the present invention can significantly inhibit the growth level of tumors in mice, which is significantly higher than the use of commonly used antibody drugs alone. Therefore, the FASN inhibitor combined with PD-1 antibody drugs has a significant effect on tumor immunotherapy and has good practical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is the Western blot analysis result of FASN inhibitor on GPX4 protein (A is MDA-MB-231 cells, B is SK-BR-3 cells);
[0021] Figure 2 The results of the effects of FASN inhibitors on the proliferation and migration abilities of breast cancer cells (in the figure, A is the proliferation ability; B is the migration and invasion ability);
[0022] Figure 3 The results are as follows: the effects of FASN inhibitor combined with ferroptosis inhibitor on the proliferation and migration ability of breast cancer cells (A is the proliferation ability; B is the migration and invasion ability);
[0023] Figure 4 The results of the effect of FASN inhibitor combined with PD-1 antibody on tumor growth (A is the tumor volume graph; B is the result of IHC analysis of CD8 protein expression level in tumor tissue). DETAILED DESCRIPTION
[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described below are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0025] In order to more clearly explain and illustrate the technical solution and implementation of the present invention, several preferred specific embodiments for implementing the technical solution of the present invention are introduced below.
[0026] The embodiments of the present invention are as follows:
[0027] The use of FASN inhibitors combined with PD-1 antibody drugs in the preparation of immunotherapy drugs for breast cancer. Wherein, the cancer is breast cancer. The FASN inhibitors include but are not limited to orlistat. Wherein, the PD-1 antibody drugs include but are not limited to atezolizumab.
[0028] The embodiment of the present invention further provides a drug, the active ingredients of which include: a FASN inhibitor and a PD-1 antibody drug, wherein the drug also includes pharmaceutically acceptable excipients.
[0029] The following is the experimental situation of the implementation scheme of the present invention:
[0030] Experimental reagents:
[0031] MDA-MB-231 and SK-BR-3 breast cancer cell lines were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences, FASN inhibitor orlistat and ferroptosis inhibitor Fer-1 were purchased from MCE (China); 0.25% trypsin was purchased from Gibco (containing EDTA). GPX4 antibody was purchased from Wuhan Mitaka Company. Fetal bovine serum (FBS), DMEM complete medium and L-15 complete medium are all commonly used drugs by technicians in this field, and the preparation and use methods are all common knowledge in the field.
[0032] The following are specific examples of implementation schemes of the present invention:
[0033] Example 1: FASN inhibitors reduce GPX4 protein levels
[0034] In this Example 1, the effect of the FASN inhibitor orlistat on the GPX4 protein level was verified, and the specific operation steps are as follows:
[0035] MDA-MB-231 and SK-BR-3 cells were routinely cultured in L-15 and DMEM complete medium containing 10% fetal bovine serum (FBS), respectively. When the confluence reached 80% under a microscope, they were digested with 0.25% trypsin and seeded in 6-well plates at 37°C and 5% CO. 2 When the cells were grown overnight in an incubator and the density reached 70%-90% of the wells, dimethyl sulfoxide (DMSO) was used as the control group and orlistat was used as the experimental group, and the cells were treated for 48 hours. The treated cells were lysed and Western blot was used to analyze the expression of GPX4 protein. The analysis results are shown in Figure 1 shown.
[0036] Figure 1 This is a Western blot analysis of FASN inhibitors on GPX4 protein; in the figure, (A) is MDA-MB-231 cells, (B) is SK-BR-3 cells. Actin is an internal reference protein. Figure 1 It can be seen that the FASN inhibitor orlistat has an inhibitory effect on the expression of GPX4 protein in both MDA-MB-231 cells and SK-BR-3 cells.
[0037] Example 2: FASN inhibitors inhibit the proliferation and migration of breast cancer cells by promoting ferroptosis
[0038] In this Example 2, the effects of the FASN inhibitor orlistat on the proliferation and migration of breast cancer cells were verified. The specific steps are as follows:
[0039] MDA-MB-231 and SK-BR-3 cells were routinely cultured in L-15 and DMEM complete medium containing 10% fetal bovine serum (FBS). When the confluence reached 80% under a microscope, they were digested with 0.25% trypsin and seeded in 6-well plates at 37°C and 5% CO. 2 Incubate overnight in an incubator and when the density grows to 70%-90% of the well, treat the cells for 24 hours with DMSO as the control group, orlistat (50nM), Fer-1 (10nM), orlistat (50nM) + Fer-1 (10nM) as the experimental group. Digest with 0.25% trypsin, centrifuge and discard the supernatant, resuspend in 1mL complete medium, count the cells, and plate 2000 cells per well in a 96-well plate. Add complete medium: cck8 reagent (9:1) at 24h, 48h and 72h, and measure the absorbance at 450nm after 1h. Treat the cells as described above, resuspend in 1 mL serum-free medium, count the cells, dilute with matrix gel: serum-free medium (1:8), add 100 μl to each Transwell chamber, and incubate in a 37°C, 5% CO2 incubator for 3 h. Aspirate the excess liquid, check for leaks and hydrate with serum-free medium, add 50,000 of the above resuspended cells to each chamber, add L-15 containing 15% fetal bovine serum and DMEM complete medium to the lower chamber, discard the medium after 30 h, wash twice with PBS, add 4% tissue fixative for 15 min, discard the tissue fixative, and wash with ddH 2 O, wash twice, add crystal violet solution to stain for 5 minutes, wash away the crystal violet solution, and take pictures under an upright microscope.
[0040] like Figure 2 As shown, it is the effect of FASN inhibitor on the proliferation and migration ability of breast cancer cells; in the figure, A is the proliferation ability; B is the migration and invasion ability. Figure 2 It can be seen that the FASN inhibitor orlistat has an inhibitory effect on the proliferation and migration ability of MDA-MB-231 cells and SK-BR-3 cells.
[0041] like Figure 3 As shown, it is the effect of FASN inhibitor combined with ferroptosis inhibitor on the proliferation and migration ability of breast cancer cells; in the figure, A is the proliferation ability; B is the migration and invasion ability. Figure 3It can be seen that the FASN inhibitor orlistat has an inhibitory effect on the proliferation and migration ability of MDA-MB-231 cells and SK-BR-3 cells by promoting ferroptosis.
[0042] Example 3: FASN inhibitor combined with PD-1 antibody significantly inhibits tumor growth
[0043] In this Example 3, the effect of FASN inhibitor orlistat combined with PD-1 antibody on tumor growth was verified, and the specific operation steps are as follows:
[0044] 4T1 cells (1X10 7 / mL, 0.1mL of each was inoculated subcutaneously in the axilla of the right forelimb of mice) was inoculated subcutaneously in the axilla of the right forelimb of BALB / c mice, and the inoculated mice were randomly divided into four groups:
[0045] PBS control group: intraperitoneal injection of the same amount of solvent three times a week, and continuous observation for 21 days;
[0046] Orlistat group: Orlistat was injected intraperitoneally, 240 mg / kg, three times a week, and observed for 21 days;
[0047] PD-1 group: intraperitoneal injection of PD-1, 200ug / mouse, three times a week, and continuous observation for 21 days;
[0048] Orlistat+PD-1 group: Orlistat was injected intraperitoneally at 240 mg / kg, and PD-1 was injected intraperitoneally at 200 ug / mouse, three times a week, and the animals were observed for 21 days.
[0049] The tumor volume was measured weekly for 4 weeks, and the mice were finally killed by cervical dislocation. The tumor volume calculation formula = 1 / 2 (length × width 2). IHC was used to analyze the expression level of CD8 protein in tumor tissues. The results were as follows: Figure 4 shown.
[0050] Figure 4 The results of the effect of FASN inhibitor combined with PD-1 antibody on tumor growth; in the figure, A is the tumor volume diagram; B is the result of IHC analysis of CD8 protein expression level in tumor tissue. Figure 4 It can be seen that the combination of FASN inhibitor orlistat and antibody drug PD-1 can significantly inhibit tumor growth, which is related to the enhanced expression of CD8 protein in tumor tissue.
[0051] In summary, the present invention has confirmed through a large number of experiments that FASN inhibitors can significantly reduce GPX4 protein levels and inhibit GPX4 gene expression, and further, when used in combination with PD-1 antibody drugs, the tumor immunotherapy effect of PD-1 antibodies can be increased, and tumor growth can be better inhibited; compared with single PD-1 antibody treatment, the FASN inhibitor combined with PD-1 antibody disclosed in the present invention can significantly inhibit the growth level of tumors in mice, which is significantly higher than the use of commonly used antibody drugs alone. Therefore, FASN inhibitors combined with PD-1 antibody drugs have a significant effect on tumor immunotherapy and have good practical value.
[0052] It is worth noting that the present invention is the first to propose that FASN inhibitors combined with PD-1 antibody drugs have a significant effect in tumor immunotherapy and has great practical value.
[0053] Compared with the prior art, the present invention provides a new drug treatment method and an optimization plan for breast cancer patients; moreover, orlistat, a FASN inhibitor, is a commonly used drug in clinical practice, and its safety has been widely verified, and it can be quickly put into clinical research and application.
[0054] The present invention is not limited to the above-mentioned optimal implementation mode. Anyone should be aware that any structural changes made under the inspiration of the present invention, and any technical solutions that are the same or similar to the present invention, fall within the protection scope of the present invention. Finally, it should be noted that the structures, proportions, sizes, etc. illustrated in the drawings of this specification are only used to match the contents disclosed in the specification for people familiar with this technology to understand and read, and are not used to limit the restrictive conditions that can be implemented in this application, so they have no technical substantive significance. Any structural modification, change in proportional relationship or adjustment of size, without affecting the effects that can be produced by this application and the purposes that can be achieved, should still fall within the scope that can be covered by the technical content disclosed in this application.
Claims
1. Application of FASN inhibitors in the preparation of immunotherapy drugs for cancer.
2. The use according to claim 1, characterized in that: The cancer is breast cancer.
3. The use according to claim 2, characterized in that: The FASN inhibitors include but are not limited to orlistat.
4. Application of FASN inhibitors combined with PD-1 antibody drugs in the preparation of immunotherapy drugs for breast cancer.
5. The use according to claim 4, characterized in that: The PD-1 antibody drugs include but are not limited to atezolizumab.
6. A drug, characterized in that The active ingredients of the drug include: FASN inhibitor and PD-1 antibody drug.
7. The drug according to claim 6, characterized in that The drug also includes pharmaceutically acceptable excipients.
